13 Nov
2017
16:15 E.S.T.

Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017

Read more

06 Nov
2017
19:00 E.S.T.

FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN

Read more

01 Nov
2017
16:15 E.S.T.

Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting

Read more

01 Nov
2017
16:15 E.S.T.

Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting

Read more

04 Oct
2017
16:30 E.S.T.

Mathieu Simon, M.D. Cellectis’ EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer

Read more

04 Sep
2017
22:30 E.S.T.

Cellectis to Participate in Upcoming Investor Conferences

Read more

04 Sep
2017
22:15 E.S.T.

Cellectis Reports Clinical Hold of UCART123 Studies

Read more

17 Aug
2017
16:30 E.S.T.

Cellectis’ UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center

Read more

02 Aug
2017
16:30 E.S.T.

Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2017

Read more

25 Jul
2017
16:01 E.S.T.

Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering

Read more